DMSG - Deutsche Multiple Sklerose Gesellschaft Bundesverband e.V.

Literaturliste Immunmodulatorische Stufentherapie der Multiplen Sklerose - Neue Aspekte und praktische Umsetzung - II. Ergänzung: März 2002


1. MSTKG (1999) Immunmodulatorische Stufentherapie der multiplen Sklerose.Nervenarzt
70:371 –386

2. MSTGK (2001) Immunmodulatorische Stufentherapie der Multiplen Sklerose: I. Ergänzung
Dezember 2000. Nervenarzt 72:150 –157

3. Report of the Quality Standards Subcommittee of the American Academy of Neurology (1994)
Practise advisory on selection of patients with multiple sclerosis for treatment with Betaseron®. Neurology 44:1537 –1540

4. Goodin D, Frohman E, Garmany G et al.(2002): Disease modifying therapies in multiple sclero-
sis –Report of the therapeutics and technology assessment subcommittee of the american academy of neurology and the MS council for clinical practice guidelines.Neurology, 58:169 –178

5. McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F (2001): Recommended
diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis.Ann Neurol 50:121 –127

6. Kobelt G, Lindgren P, Smala A, Rieckmann P, Group GCoMS (2001): Costs and Quality of Life in Multiple Sclerosis. An observational study in Germany. Health Economies in Prevention and Care
2:60 –68

7. Noseworthy J, Gold R, Hartung HP (1999): Treatment of multiple sclerosis:recent trials and future perspectives.Curr Opin Neurol 12:279 –293

8. Clanet M, Kappos L, Radü E et al.(2001)Results of the European Interferon beta-1a (Avonex) Dose-Comparison Study.J Neurol 248 [Suppl 2 ]:63

9. OWIMS Study Group (1999)OWIMS –Evidence of interferon beta-1a dose response in relapsing-remitting multiple sclerosis.Neurology 53:679 –686

10. Jacobs LD,Cookfair DL,Rudick RA et al.(1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285 –294

11. Färkkila M, Evidence-Study Group (2001): The Evidence study: Direct comparative study of IFN beta-1a three times weekly (Rebif ®)andonce weekly (Avonex ®)in RRMS.Mult Scler7 [Suppl 1 ]P-305

12. Durelli L,Verdun E,Barbero P,Bergui M, Versino E,Ghezzi A,Montanari E et al.(2002): Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis:results of a 2-year prospective randomised multicentre study (INCOMIN). The Lancet 359:1453 –1460

13. Comi G, Filippi M, Wolinsky J (2001)European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol
49:290 –297

14. Filippi M, Rovaris M, Rocca M et al.(2001)Glatiramer acetate reduces the proportion of new MS lesions evolving into „black holes “. Neurology 57:731 –733

15. Neuhaus O, Farina C, Wekerle H, Hohlfeld R (2001): Mechanisms of action of glatiramer acetate in multiple sclerosis.Neurology 56:702 –708

16. Soelberg-Soerensen P (2001):ESIMS.European Charcot Foundation 2001;Venice 10 –21,2001.

17. National Multiple Sclerosis Society of USA (1998). Disease management consensus statement. Internet:; 1:4

18. Oger J, Freedman M (1999)Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 26:294

19. Lublin F, Reingold S et al.(2001)Placebo controlled clinical trials in multiple sclerosis: Ethical considerations. Ann Neurol 49:677-681

20. Emanuel E, Miller F (2001): The ethics of placebo-controlles trials – a middle ground. N Engl J Med 345:915 –919

21. Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN (2000): Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology 54:2039 –2044

22. Grauer O, Offenhäuser M, Schmidt J, Toyka K, Gold R (2001): Glukokortikosteroid- Therapie bei Optikusneuritis und Multipler Sklerose. Nervenarzt 72:577 –589

23. Sellebjerg F, Nielsen H, Frederiksen J, Oelsen J (1999): A randomized, controlled trial of oral high-dose methylprednisolone in acute opticneuritis.Neurology 52:1479 –1484

24. Brex PA, Jenkins R, Fox NC et al.(2000): Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54:1689 –1691

25. Zivadinov R, De Masi R, Nasuelli D et al.(2001): MRI techniques and cognitive impairment in the early phase of relapsing- remitting multiple sclerosis. Neuroradiology 43:272 –278

26. Weinshenker B, O'Brien P, Petterson T et al. (1999): A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.Ann Neurol 46:878 –886

27. Keegan M, Pineda A, McClelland R (2002): Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58:143 –146

28. Oliveri R, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F (1998): Randomized trial comparing two different high doses of methylprednisolone in MS.Neurology 50:1833 –1836

29. Zividinov R, Rudick R, De Masi R (2001): Effects of IV methylprednisolone on brain atrophy in relapsing- remitting MS.Neurology 57:1239 –1247

30. Kümpfel T, Schumann E, Then Bergh F et al. (2001): Monthly high-dose methylprednisolone pulse therapy in patients with multiple sclerosis: An MRI controlled study with single crossover design. Neurology 56:A76

31. Pette M, Zettl U (2002): The use of multiple sclerosis databases at neurological university hospitals in Germany. Multiple Sclerosis (in press)

32. Flachenecker P; Zettl UK (2001): Aufbau und Entwicklung eines epidemiologischen MS-Registers mit Hilfe einer Internet-Datenbank unter Federführung der Deutschen- Multiple- Sklerose- Gesellschaft (DMSG)[Abstr ]. Akt Neurol 28 [Suppl 2 ]:118

33. Gass A, Radü E, Filippi M, Kappos L (1999): Kernspintomographische Diagnostik und Ver-laufsuntersuchungen bei Multipler Sklerose – Ein Leitfaden für die Qualitätssicherung. Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. Rö Fp 170:581 –586

34. Sibley A, Bamford CR, Clark K (1985): Clinical viral infections and multiple sclerosis. Lancet
1313 –1315

35. Benoist C, Mathis D (2001): Autoimmunity provoked by infection: how good is the case for T-cellepitope mimicry? Nat Immunol 2:797 –801

36. STIKO (2001)Impfempfehlungen. Dtsch Ärztebl 16 [Suppl ]:3 –18

37. Gellin B, Schaffner W (2001): The risk of vaccination – the importance of „negative “studies (Editorial). New Engl J Med 344:372 –373

38. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S (2001): Vaccination and the risk of
relapse in multiple sclerosis. N Engl J Med 344:319 –336

39. Miller AE, Morgante LA, Buchwald LY et al. (1997): A multicenter, randomized, doubleblind, placebo- controlled trial of influenza immunization in multiple sclerosis.Neurology 48:312 –314

40. De Keyser J, Zwaniken C, Boon M (1998): Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159:51 –53

41. De Keyser J (1998): Safety of tetanus vaccination in relapsing- remitting multiple sclerosis. Infection 26:319

42. Moriabadi N, Niewiesk S, Kruse N et al.(2001): Influenza vaccination in MS:Absence of T-cell response against white matter proteins. Neurology 56:938 –943

43. Ascherio A, Zhang S, Hernan M et al.(2001): Hepatitis B vaccination and the risk of multiple sclerosis .N Engl J Med 344:327 –332

44. Zipp F, Weil JG ,Einhäupl KM (1999):No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5:964 –965

45. Baumhackl U, Franta C, Retzl J, Salomonwitz E, Eder G (2002):A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis:clinical, immunological and MRI results. Vaccine (in press)

46. Thompson A, Montalban X, Barkhof F et al. (2000): Diagnostic criteria for primary progressive multiple sclerosis:a position paper. Ann Neurol 47:831 –835

47. Barkhof F, Filippi M, Miller D et al.(1997): Comparision of MRI criteria at first presentation to predict co version to clinically definite multiple sclerosis.Brain 120:2059 –2069

48. Tintore M, Rovira A, Martinez M et al.(2000): Isolated demyelinating syndromes:comparison of different MR imaging criteria to predict co version to clinically definite multiple sclerosis. Am J Neuroradiol 21:702 –706

- 31.10.2002